Short Summary
Merck Sharp & Dohme Corp. filed a suit seeking permanent injunction against Everest Organics Limited for infringing its registered patent No. 209816, which covers the molecule SITAGLIPTIN. The Plaintiffs alleged that the Defendant was developing and preparing to commercialize an infringing product. Based on the prima facie case presented, the Court granted an ad-interim ex-parte injunction.
Detailed Summary
In the high-stakes world of pharmaceuticals, the gap between a patent expiring and a generic launch can be worth hundreds of crores. When a competitor begins preparing to commercialize a patented molecule, the original innovator has only one real weapon: the courts. This case shows exactly how that weapon is deployed when time is running out and the threat of irreparable harm looms large.
Merck Sharp & Dohme Corp. and another plaintiff, the innovators behind the molecule Sitagliptin, held registered Patent No. 209816 covering that compound. Sitagliptin is a well-known pharmaceutical molecule used in diabetes treatment, and the patent represented years of research, clinical trials, and regulatory investment. The defendant, Everest Organics Limited, was allegedly developing and preparing to commercialize a product that the plaintiffs believed infringed their patent rights. Rather than wait for an actual launch to seek relief, Merck moved the court proactively, filing a suit for permanent injunction to stop the alleged infringement in its tracks.
The plaintiffs argued that Everest Organics was gearing up to bring an infringing product to market, which would directly violate their exclusive rights under Patent No. 209816. They presented enough material to convince the court that a strong prima facie case of infringement existed, and that waiting until the product was actually launched would cause them irreparable harm that no monetary award could later undo. The defendant, having been served notice of an ex-parte application, had limited opportunity to counter at this stage. The core legal friction was simple but urgent: should the court step in before any commercial sale had even occurred, based solely on the plaintiffs' prima facie showing and the risk of imminent irreparable loss?
The court was satisfied that the plaintiffs had made out a strong prima facie case of patent infringement. It found that the balance of convenience clearly favored Merck, and that the threat of irreparable injury to the patent holder justified immediate intervention. On 8 May 2020, the court granted an ad-interim ex-parte injunction in favor of Merck Sharp & Dohme Corp., restraining Everest Organics Limited from commercializing the allegedly infringing product. The matter was treated as an interim order, meaning the injunction would hold until further hearing, but the immediate effect was decisive: the defendant could not move forward with its planned launch while the dispute was being adjudicated.
For founders and IP professionals in pharma and other patent-driven industries, this case is a clear reminder that the law allows you to act before the damage is done. If you hold a valid patent and you have credible evidence that a competitor is preparing to launch an infringing product, you do not have to wait for the first sale to seek relief. Build a strong prima facie case, demonstrate the likelihood of irreparable harm, and show that the balance of convenience tilts your way. Courts will grant interim injunctions to preserve your exclusive rights, but only if you move quickly and present your evidence convincingly. Proactive enforcement, not reactive litigation, is what protects the value of your patent.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Merck Sharp & Dohme Corp. vs Everest Organics Limited is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
The North Face Apparel CorpvsController of Patents and Designs
The North Face Apparel Corp challenged the Controller of Patents' refusal of its patent application (No. 202147026139) titled 'Systems and Methods for End-to-End Article Management' before the Madras High Court under Section 117A of the Patents Act, 1970. The Controller had rejected the application citing lack of inventive step over prior art documents D21-D24. The Court held that the Controller erred by dissecting the claims into isolated elements rather than assessing the invention as a whole, and overlooked the use of spectrophotometer and invisible markers for tracking the manufacturing process, which were not disclosed in the cited prior art. The appeal was allowed and the Controller was directed to grant the patent.
Aventose Energy Private LimitedvsThe Assistant Controller of Patents & Designs, Patent Office Chennai
Aventose Energy Private Limited appealed under Section 117A of the Patents Act, 1970 against the refusal of its patent application (No. 202141019671) for a 'System and Method for Operating Automobiles with an Electric Drivetrain' featuring safe mode activation upon fault detection. The Madras High Court found that the Assistant Controller had contradicted the First Examination Report (which accepted novelty) by subsequently holding the invention lacked novelty without giving the applicant an opportunity to be heard. The court further held that the Controller improperly conflated novelty with inventive step under Section 2(1)(ja) and failed to properly analyze the claims against prior art documents D1–D4.
Apex Laboratories Pvt LtdvsElder Lifescience and Ambico Ayurvedic Health Care
Apex Laboratories Pvt Ltd, the prior adopter and registered proprietor of the trademark ZINCOVIT (TM No. 487453 in Class 5) since 1988, sought interim injunction against Elder Lifescience and Ambico Ayurvedic Health Care for using the deceptively similar mark NEO ZINCOVIT. The applicant also claimed copyright infringement of its registered artistic works (A-108878/2014) covering colour scheme, get-up, and layout. The Madras High Court was satisfied that the respondents were attempting to piggyback on the applicant's goodwill and granted interim injunctions on all three applications covering trademark infringement, copyright infringement, and passing off.
Radico Khaitan LimitedvsPicadilly Agro Industries Limited
This Special Leave Petition arose from a judgment dated 29-05-2026 in CS No. 8/2025 passed by the District Judge, Karnal, Haryana, concerning a trademark dispute over the marks 'Cashmere' and 'Kashmyr' used in relation to beer and vodka. The Supreme Court noted that a First Appeal (FAO-COM-11-2026) was already pending before the Division Bench of the Punjab and Haryana High Court, listed for 28.10.2026. The Court disposed of the SLP without adjudicating it on merits, requesting the High Court to pass an appropriate order regarding the ad interim injunction on the scheduled date.
Maharaja Agrasen Technical Educational Society (Regd.)vsMaharaja Agrasen Himalayan Garhwal University
The plaintiff, Maharaja Agrasen Technical Educational Society, filed a suit for permanent injunction against the defendant, Maharaja Agrasen Himalayan Garhwal University, alleging infringement and passing off regarding the use of the words 'Maharaja Agrasen' in the defendant's name. The Delhi High Court had previously granted a restraint order on 10.07.2026. During the pendency of the suit, the parties arrived at a settlement dated 14.09.2026, under which the defendant agreed to change its name through a statutory amendment while being permitted limited transitional use of its existing name. The court recorded the settlement, modified the interim order accordingly, and listed the matter for compliance reporting on 13.07.2027.
Varahi Diamonds And Finance LimitedvsSahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr.
This is a commercial suit filed by Varahi Diamonds And Finance Limited against Sahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr. before the Delhi High Court. The order is primarily procedural, dealing with the registration of the plaint, issuance of summons, directions for filing pleadings, and an interim injunction application. The matter was referred to mediation, with parties directed to appear before the Delhi High Court Mediation and Conciliation Centre.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.